Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2015, Article ID 538137, 5 pages
http://dx.doi.org/10.1155/2015/538137
Case Report

Fatal Cytomegalovirus Disease after Combination Therapy with Corticosteroids and Rituximab for Granulomatosis with Polyangiitis

Department of Internal Medicine, University of Kentucky College of Medicine, Charles T. Wethington Building 304B, 900 South Limestone Street, Lexington, KY 40536, USA

Received 21 October 2014; Accepted 29 December 2014

Academic Editor: Suleyman Serdar Koca

Copyright © 2015 Talal Hilal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Finkielman, A. S. Lee, A. M. Hummel et al., “ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis,” The American Journal of Medicine, vol. 120, no. 7, pp. 643.e9–643.e14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Varani and M. Landini, “Cytomegalovirus-induced immunopathology and its clinical consequences,” Herpesviridae, vol. 2, no. 1, article 6, 2011. View at Publisher · View at Google Scholar
  3. S. A. S. Staras, S. C. Dollard, K. W. Radford, W. D. Flanders, R. F. Pass, and M. J. Cannon, “Seroprevalence of cytomegalovirus infection in the United States, 1988–1994,” Clinical Infectious Diseases, vol. 43, no. 9, pp. 1143–1151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Wadhawan, S. Gupta, N. Goyal et al., “Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience,” Liver Transplantation, vol. 18, no. 12, pp. 1448–1455, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Sandherr II, H. Einsele, H. Hebart et al., “Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the infectious diseases working party (AGIHO) of the German society for hematology and oncology (DGHO),” Annals of Oncology, vol. 17, no. 7, pp. 1051–1059, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Slifkin, S. Doron, and D. R. Snydman, “Viral prophylaxis in organ transplant patients,” Drugs, vol. 64, no. 24, pp. 2763–2792, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Meijer, G. J. Boland, and L. F. Verdonck, “Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants,” Clinical Microbiology Reviews, vol. 16, no. 4, pp. 647–657, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. F. G. Frantzeskaki, E.-S. Karampi, C. Kottaridi et al., “Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers,” Journal of Critical Care, 2014. View at Publisher · View at Google Scholar
  9. C. H. Cook, “Cytomegalovirus reactivation in ‘immunocompetent’ patients: a call for scientific prophylaxis,” The Journal of Infectious Diseases, vol. 196, no. 9, pp. 1273–1275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. C. A. Biron, K. S. Byron, and J. L. Sullivan, “Severe herpesvirus infections in an adolescent without natural killer cells,” The New England Journal of Medicine, vol. 320, no. 26, pp. 1731–1735, 1989. View at Publisher · View at Google Scholar · View at Scopus
  11. W. D. Döcke, S. Prösch, E. Fietze et al., “Cytomegalovirus reactivation and tumour necrosis factor,” The Lancet, vol. 343, no. 8892, pp. 268–269, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Söderberg-Nauclér, “HCMV microinfections in inflammatory diseases and cancer,” Journal of Clinical Virology, vol. 41, no. 3, pp. 218–223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. F. Meyer, B. Hellmich, S. Kotterba, and H. Schatz, “Cytomegalovirus infection in systemic necrotizing vasculitis: causative agent or opportunistic infection?” Rheumatology International, vol. 20, no. 1, pp. 35–38, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Mori, H. Kameda, H. Ogawa et al., “Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy,” Journal of Rheumatology, vol. 31, no. 7, pp. 1349–1351, 2004. View at Google Scholar · View at Scopus
  15. Y. Kabata, G. Takahashi, and H. Tsuneoka, “Cytomegalovirus retinitis treated with valganciclovir in Wegener's granulomatosis,” Clinical Ophthalmology, vol. 6, no. 1, pp. 521–523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Varani, A. Mastroianni, G. Frascaroli et al., “Generalized Wegener's granulomatosis in an immunocompetent adult after cytomegalovirus mononucleosis and bacterial urinary tract infection,” Arthritis and Rheumatism, vol. 60, no. 5, pp. 1558–1562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Chibane, S. Feldman-Billard, I. Rossignol, R. Kassaei, F. Mihoubi-Mantout, and E. Héron, “Short-term tolerance of three days pulse methyprednisolone therapy: a prospective study in 146 patients,” Revue de Medecine Interne, vol. 26, no. 1, pp. 20–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. J. Patel, J. M. Devos, R. J. Knight et al., “Effects of rituximab on the development of viral and fungal infections in renal transplant recipients,” ISRN Transplantation, vol. 2013, Article ID 819025, 8 pages, 2013. View at Publisher · View at Google Scholar
  19. S. Aksoy, H. Harputluoglu, S. Kilickap et al., “Rituximab-related viral infections in lymphoma patients,” Leukemia and Lymphoma, vol. 48, no. 7, pp. 1307–1312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Sharma, J. Moore, V. Nguyen, and K. van Besien, “Fatal CMV pneumonitis in a lymphoma patient treated with rituximab,” American Journal of Hematology, vol. 84, no. 9, pp. 614–616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M.-Y. Lee, T.-J. Chiou, L.-T. Hsiao et al., “Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation,” Annals of Hematology, vol. 87, no. 4, pp. 285–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Balthesen, M. Messerle, and M. J. Reddehase, “Lungs are a major organ site of cytomegalovirus latency and recurrence,” Journal of Virology, vol. 67, no. 9, pp. 5360–5366, 1993. View at Google Scholar · View at Scopus